SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study - potential challenge for vaccines and therapies
- PMID: 33931941
- PMCID: PMC8185546
- DOI: 10.15252/emmm.202114062
SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study - potential challenge for vaccines and therapies
Abstract
Scientists and the public were alarmed at the first large viral variant of SARS-CoV-2 reported in December 2020. We have followed the time course of emerging viral mutants and variants during the SARS-CoV-2 pandemic in ten countries on four continents. We examined > 383,500 complete SARS-CoV-2 nucleotide sequences in GISAID (Global Initiative of Sharing All Influenza Data) with sampling dates extending until April 05, 2021. These sequences originated from ten different countries: United Kingdom, South Africa, Brazil, United States, India, Russia, France, Spain, Germany, and China. Among the 77 to 100 novel mutations, some previously reported mutations waned and some of them increased in prevalence over time. VUI2012/01 (B.1.1.7) and 501Y.V2 (B.1.351), the so-called UK and South Africa variants, respectively, and two variants from Brazil, 484K.V2, now called P.1 and P.2, increased in prevalence. Despite lockdowns, worldwide active replication in genetically and socio-economically diverse populations facilitated selection of new mutations. The data on mutant and variant SARS-CoV-2 strains provided here comprise a global resource for easy access to the myriad mutations and variants detected to date globally. Rapidly evolving new variant and mutant strains might give rise to escape variants, capable of limiting the efficacy of vaccines, therapies, and diagnostic tests.
Keywords: South African and Brazil variants; UK variant B.1.1.7; high incidence of C to T transitions; numerous new mutations; time course of SARS-CoV-2 mutant emergence.
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?J Korean Med Sci. 2021 May 10;36(18):e124. doi: 10.3346/jkms.2021.36.e124. J Korean Med Sci. 2021. PMID: 33975397 Free PMC article. Review.
-
Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein.Water Res. 2021 Jun 1;197:117104. doi: 10.1016/j.watres.2021.117104. Epub 2021 Apr 2. Water Res. 2021. PMID: 33857895 Free PMC article.
-
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21. Epub 2021 Aug 31. mBio. 2021. PMID: 34465019 Free PMC article.
-
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312. Elife. 2020. PMID: 33112236 Free PMC article.
-
Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.Viruses. 2021 Jun 18;13(6):1171. doi: 10.3390/v13061171. Viruses. 2021. PMID: 34207378 Free PMC article. Review.
Cited by
-
Analysis of SARS-CoV-2 Spike Protein Variants with Recombinant Reporter Viruses Created from a Bacmid System.Int J Mol Sci. 2023 May 2;24(9):8156. doi: 10.3390/ijms24098156. Int J Mol Sci. 2023. PMID: 37175863 Free PMC article.
-
SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients.iScience. 2023 May 19;26(5):106604. doi: 10.1016/j.isci.2023.106604. Epub 2023 Apr 7. iScience. 2023. PMID: 37091988 Free PMC article.
-
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.iScience. 2023 Feb 17;26(2):105949. doi: 10.1016/j.isci.2023.105949. Epub 2023 Jan 10. iScience. 2023. PMID: 36644321 Free PMC article.
-
Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Front Microbiol. 2022 Oct 26;13:915202. doi: 10.3389/fmicb.2022.915202. eCollection 2022. Front Microbiol. 2022. PMID: 36386681 Free PMC article.
-
Comparison of Intracellular Transcriptional Response of NHBE Cells to Infection with SARS-CoV-2 Washington and New York Strains.Front Cell Infect Microbiol. 2022 Sep 20;12:1009328. doi: 10.3389/fcimb.2022.1009328. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36204651 Free PMC article.
References
-
- Anant S, Davidson NO (2001) Molecular mechanisms of apolipoprotein B mRNA editing. Curr Opin Lipidol 12: 159–165 - PubMed
-
- Annavajhala MK, Mohri H, Zucker JE, Sheng Z, Wang P, Gomez‐Simmonds A, Ho DD, Uhlemann A‐C (2021) A novel SARS‐CoV‐2 variant of concern, B.1.526, identified in New York. medRxiv 10.1101/2021.02.23.21252259 [PREPRINT] - DOI
-
- Burioni R, Topol E (2021) Assessing the human immune response to SARS‐CoV‐2 variants. Nat Med 27: 571–572 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
